Cited by 1,134Melanoma and MAPK PathwaysLung Cancer Treatments and MutationsCancer Mechanisms and Therapy

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Open access

Wilson, Timothy R., Fridlyand, Jane, Yan, Yibing, Penuel, Elicia, Burton, Luciana, Chan, Emily, Peng, Jing, Lin, Eva, Wang, Yulei, Sosman, Jeff, Ribas, Antoni, Li, Jiang, Moffat, John, Sutherlin, Daniel P., Koeppen, Hartmut, Merchant, Mark, Neve, Richard, Settleman, Jeff·2012·Nature

DOI 10.1038/nature11249PMC PMC3724525

Open this paper in CoChat — free account

Abstract

Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy. However, the efficacy of kinase inhibitors in patients whose tumours harbour such alleles is invariably limited by innate or acquired drug resistance. The identification of resistance mechanisms has revealed a recurrent theme—the engagement of survival signals redundant to those transduced by the targeted kinase. Cancer cells typically express multiple receptor tyrosine kinases (RTKs) that mediate signals that converge on common critical downstream cell-survival effectors—most notably, phosphatidylinositol-3-OH kinase (PI(3)K) and mitogen-activated protein kinase (MAPK). Consequently, an increase in RTK-ligand levels, through autocrine tumour-cell production, paracrine contribution from tumour stroma or systemic production, could confer resistance to inhibitors of an oncogenic kinase with a similar signalling output. Here, using a panel of kinase-'addicted' human cancer cell lines, we found that most cells can be rescued from drug sensitivity by simply exposing them to one or more RTK ligands. Among the findings with clinical implications was the observation that hepatocyte growth factor (HGF) confers resistance to the BRAF inhibitor PLX4032 (vemurafenib) in BRAF-mutant melanoma cells. These observations highlight the extensive redundancy of RTK-transduced signalling in cancer cells and the potentially broad role of widely expressed RTK ligands in innate and acquired resistance to drugs targeting oncogenic kinases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature11249

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1477 · Cited by 1,817
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Self-citation
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059

Flagged first, then by citations

Show all 29 references

Sorted by citations

Items 401–500 of 1,000

Consideration of the cellular microenvironment: Physiologically relevant co-culture systems in drug discovery
Berg, E. L., Hsu, Y.-C., & Lee, J. A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.013 · Cited by 57
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations
Traer, E. A., Javidi‐Sharifi, N., Agarwal, A., Dunlap, J. B., English, I. A., Martinez, J., Tyner, J. W., Wong, M., & Druker, B. J. (2014) · Blood · doi:10.1182/blood-2013-07-518381 · Cited by 52
Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies
Bagrodia, S., Smeal, T., & Abraham, R. T. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12007 · Cited by 56
NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth
Bailey, S. T., Miron, P. L., Choi, Y. J., Kochupurakkal, B. S., Maulik, G., Rodig, S. J., Tian, R., Foley, K. M., Bowman, T. V., Miron, A., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0206-t · Cited by 53
Fibroblasts, an inconspicuous but essential player in colon cancer development and progression
Mukaida, N., & Sasaki, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i23.5301 · Cited by 54
Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing
Selt, F., Buhl, J. L., Hielscher, T., Sahm, F., Capper, D., Korshunov, A., Usta, D., Brabetz, S., Ridinger, J., Ecker, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14004 · Cited by 55
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
Sampera, A., Sánchez-Martín, F. J., Arpí, O., Visa, L., Iglesias, M., Menéndez, S., Gaye, É., Dalmases, A., Clavé, S., Gelabert‐Baldrich, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0455 · Cited by 56
A mass spectrometry-based proteome map of drug action in lung cancer cell lines
Ruprecht, B., Bernardo, J. D., Wang, Z., Mo, X., Ursu, O., Christopher, M., Fernandez, R. B., Zheng, L., Dill, B. D., Wang, H., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0572-3 · Cited by 53
RasGRP Ras guanine nucleotide exchange factors in cancer
Ksionda, O., Limnander, A., & Roose, J. P. (2013) · Frontiers in Biology · doi:10.1007/s11515-013-1276-9 · Cited by 52
Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy
Brys, A. K., Gowda, R., Loriaux, D. B., Robertson, G. P., & Mosca, P. J. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.01.004 · Cited by 53
COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors
Xie, Y., Cao, Z., Wong, E. W. P., Guan, Y., Ma, W., Zhang, J. Q., Walczak, E. G., Murphy, D. A., Ran, L., Sirota, I., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94840 · Cited by 51
Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies
Grassberger, C., McClatchy, D. M., Geng, C., Kamran, S. C., Fintelmann, F. J., Maruvka, Y. E., Piotrowska, Z., Willers, H., Sequist, L. V. D., Hata, A. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3652 · Cited by 52
Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition
Koch, H., Busto, M. E. D. C., Kramer, K., Médard, G., & Küster, B. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00161 · Cited by 51
The Next Generation of Antibody Drug Conjugates
Mack, F. A., Ritchie, M. F., & Sapra, P. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.001 · Cited by 50
Trial Watch
Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24850 · Cited by 56
Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and “swarm intelligence”
Tarabichi, M., Antoniou, A., Saiselet, M., Pita, J. M. G., Andry, G., Dumont, J. E., Detours, V., & Maenhaut, C. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9431-y · Cited by 51
Annotation of human cancers with EGFR signaling–associated protein complexes using proximity ligation assays
Smith, M. A., Hall, R. D., Fisher, K. J., Haake, S. M., Khalil, F. K., Schabath, M. B., Vuaroqueaux, V., Fiebig, H., Altiok, S., Chen, Y. A., et al. (2015) · Science Signaling · doi:10.1126/scisignal.2005906 · Cited by 51
Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma
Azuaje, F. J., Tiemann, K., & Niclou, S. P. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0098-6 · Cited by 53
Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells
Lee, E., Ha, S., & Logan, S. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141589 · Cited by 52
Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance
Smith, M. P., & Wellbrock, C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0954 · Cited by 52
BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines
Herr, R., Halbach, S., Heizmann, M., Busch, H. S., Boerries, M., & Brummer, T. (2018) · Oncogene · doi:10.1038/s41388-017-0063-5 · Cited by 50
A Review on the Antitumor Activity of Various Nitrogenous-based Heterocyclic Compounds as NSCLC Inhibitors
Liu, J.-C., Narva, S., Zhou, K., & Zhang, W. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666190312152358 · Cited by 50
Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Guillén Díaz-Maroto, N., Sanz-Pamplona, R., Berdiel-Acer, M., Cimas, F. J., García, E., Gonçalves-Ribeiro, S., Albert, N., Garcia-Vicién, G., Capella, G., Moreno, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3957 · Cited by 51
Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
Alexander, P. B., & Wang, X. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0396-9 · Cited by 50
Microenvironmental Signals and Biochemical Information Processing: Cooperative Determinants of Intratumoral Plasticity and Heterogeneity
Davies, A. E., & Albeck, J. G. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00044 · Cited by 51
The Emerging Role of Exosomes in Cancer Chemoresistance
Li, J., Gao, N., Gao, Z., Liu, W., Pang, B., Dong, X., Li, Y., & Fan, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.737962 · Cited by 52
Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines
von der Heyde, S., Bender, C., Henjes, F., Sonntag, J., Korf, U., & Beißbarth, T. (2014) · BMC Systems Biology · doi:10.1186/1752-0509-8-75 · Cited by 50
Opportunities and challenges provided by crosstalk between signalling pathways in cancer
Prahallad, A., & Bernards, R. (2015) · Oncogene · doi:10.1038/onc.2015.151 · Cited by 50
The pharmacological point of view of resistance to therapy in tumors
Damia, G. L. M., & Garattini, S. K. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.008 · Cited by 48
Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics
Frederick, D. T., Fragomeni, R. A. S., Schalck, A. P., Ferreiro-Neira, I., Hoff, T., Cooper, Z. A., Haq, R., Panka, D. J., Kwong, L. N., Davies, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101286 · Cited by 50
Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
Chang, J., Wang, S., Zhang, Z., Liu, X., Wu, Z., Geng, R., Ge, X., Dai, C., Liu, R., Zhang, Q., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2987 · Cited by 51
HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B
Kirouac, D. C., Du, J., Lahdenranta, J., Onsum, M. D., Nielsen, U. B., Schoeberl, B., & McDonagh, C. F. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004827 · Cited by 49
MEK inhibitors for the treatment of NRAS mutant melanoma
Sarkisian, S., & Davar, D. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s131721 · Cited by 52
No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
Girotti, M. R., Saturno, G., Lorigan, P. C., & Marais, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.027 · Cited by 49
Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
Nakade, J., Takeuchi, S., Nakagawa, T., Ishikawa, D., Sano, T., Nanjo, S., Yamada, T., Ebi, H., Zhao, L., Yasumoto, K., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000170 · Cited by 48
Human Mitochondrial NAD(P)+–Dependent Malic Enzyme Participates in Cutaneous Melanoma Progression and Invasion
Chang, Y., Gao, H., Chiang, C., Wang, W., Huang, S., Ku, C.-F., Liu, G., & Hung, H. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.385 · Cited by 48
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
Gallagher, S. J., Tiffen, J. C., & Hersey, P. (2015) · Cancers · doi:10.3390/cancers7040870 · Cited by 49
Revisiting ovarian cancer microenvironment: a friend or a foe?
Zhang, B., Chen, F., Xu, Q., Han, L., Xu, J., Gao, L., Sun, X., Li, Y., Li, Y., Qian, M., et al. (2017) · Protein & Cell · doi:10.1007/s13238-017-0466-7 · Cited by 48
Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
Wang, X., Kokabee, L., Kokabee, M., & Conklin, D. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.668996 · Cited by 48
Kinase-independent role for CRAF-driving tumour radioresistance via CHK2
Advani, S. J., Camargo, M. F., Seguin, L., Mielgo, A., Anand, S., Hicks, A. M., Aguilera, J. A., Franovic, A., Weis, S. M., & Cheresh, D. A. (2015) · Nature Communications · doi:10.1038/ncomms9154 · Cited by 47
Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer
Chen, P., Hu, T., Liang, Y., Jiang, Y., Pan, Y., Li, C., Zhang, P., Wei, D., Li, P., Jeong, L. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3282 · Cited by 47
Role of HGF in epithelial–stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ
Casbas-Hernández, P., D’Arcy, M. E., Romàn-Pèrez, E., Brauer, H. A., McNaughton, K. K., Miller, S. M., Chhetri, R. K., Oldenburg, A. L., Fleming, J. M., Amos, K. D., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3476 · Cited by 48
Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma
Roesch, A., Paschen, A., Landsberg, J., Helfrich, I., Becker, J. C., & Schadendorf, D. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.023 · Cited by 47
MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
Caenepeel, S. R., Cooke, K. S., Wadsworth, S., Huang, G. N., Robert, L., Moreno, B. H., Parisi, G., Cajulis, E. E., Kendall, R. L., Beltran, P. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14855 · Cited by 47
Regorafenib reverses HGF ‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Chen, W., Yang, J., Zhang, Y., Cai, H., Chen, X., & Sun, D. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12578 · Cited by 47
Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: a systems biology perspective
Gao, X., Cai, Y., Wang, Z., He, W., Cao, S., Xu, R., & Chen, H. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2056-3 · Cited by 47
Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment
Ghosh, S., Marrocco, I., & Yarden, Y. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.002 · Cited by 48
Adaptive resistance to targeted therapies in cancer.
Rosell, R., Karachaliou, N., Morales-Espinosa, D., Costa, C., Molina‐Vila, M. Á., Sansano, I., Gascó, A., Viteri, S., Massutí, B., Wei, J., et al. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.08 · Cited by 48
Synthesis of Carbohydrate Capped Silicon Nanoparticles and their Reduced Cytotoxicity, In Vivo Toxicity, and Cellular Uptake
Ahire, J. H., Behray, M., Webster, C. A., Wang, Q., Sherwood, V., Saengkrit, N., Ruktanonchai, U., Woramongkolchai, N., & Chao, Y. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500298 · Cited by 47
The importance of cancer-associated fibroblasts in targeted therapies and drug resistance in breast cancer
Zheng, J., & Hao, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1333839 · Cited by 49
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies
Zhou, K., Liu, X., & Zhu, H. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01752-9 · Cited by 52
Achievements and Challenges of Molecular Targeted Therapy in Melanoma
Sullivan, R. J., LoRusso, P. M., Boerner, S. A., & Dummer, R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.177 · Cited by 49
Effect of Phosphorylation on EGFR Dimer Stability Probed by Single-Molecule Dynamics and FRET/FLIM
Coban, O., Zanetti-Domingues, L. C., Matthews, D. R., Rolfe, D. J., Weitsman, G. E., Barber, P. R., Barbeau, J., Devauges, V., Kampmeier, F., Winn, M., et al. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2015.01.005 · Cited by 44
Genetic modifiers of EGFR dependence in non-small cell lung cancer
Sharifnia, T., Rusu, V., Piccioni, F., Bagul, M., Imielinski, M. B., Cherniack, A. D., Pedamallu, C. S., Wong, B., Wilson, F. H., Garraway, L. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412228112 · Cited by 48
STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody
Lee, J. S., Kang, J.-H., Boo, H., Hwang, S.-J., Hong, S., Lee, S.-C., Park, Y.-J., Chung, T.-M., Youn, H., Lee, S. M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9499 · Cited by 46
Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 47
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
Schwarz, L. J., Hutchinson, K. E., Rexer, B. N., Estrada, M. V., Ericsson, P. I. G., Sanders, M. E., Dugger, T. C., Formisano, L., Zotano, Á. G., Red-Brewer, M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx065 · Cited by 48
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
Azimi, A., Tuominen, R., Svedman, F. C., Caramuta, S., Pernemalm, M., Stolt, M. F., Kanter, L., Kharaziha, P., Lehtiö, J., Johansson, C. H., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.406 · Cited by 46
Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy
Kim, E., Kim, J., Smith, M. A., Haura, E. B., & Anderson, A. R. A. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2002930 · Cited by 44
Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance
Joosten, S. P. J., Spaargaren, M., Clevers, H. C., & Pals, S. T. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188437 · Cited by 47
Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations
Bai, Y., Kim, J., Watters, J. M., Fang, B., Kinose, F., Song, L., Koomen, J. M., Teer, J. K., Fisher, K. J., Chen, Y. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0505 · Cited by 45
Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer
Fong, J., Jacobs, R. J., Moravec, D. N., Uppada, S. B., Botting, G. M., Nlend, M., & Puri, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078398 · Cited by 45
Therapeutic targeting of platelet-derived growth factor receptors in solid tumors
Ehnman, M., & Östman, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.847086 · Cited by 45
Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats
Cui, J. J., Shen, H., Tran‐Dubé, M., Nambu, M. D., McTigue, M. A., Grodsky, N. B., Ryan, K., Yamazaki, S., Aguirre, S. A., Parker, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400926x · Cited by 44
Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer
Yang, S., Huang, Y., & Zhao, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878740 · Cited by 50
When the MET receptor kicks in to resist targeted therapies
Fernandes, M., Jamme, P., Cortot, A. B., Kherrouche, Z., & Tulasne, D. (2021) · Oncogene · doi:10.1038/s41388-021-01835-0 · Cited by 51
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
Mancini, M., & Yarden, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.018 · Cited by 45
Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma
Gui, Y., Yeganeh, M., Donates, Y.-C., Tobelaim, W.-S., Chababi, W., Mayhue, M., Yoshimura, A., Ramanathan, S., Saucier, C., & Ilangumaran, S. (2015) · Oncogene · doi:10.1038/onc.2015.20 · Cited by 44
Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer
Bradley, C. A., Dunne, P. D., Bingham, V., McQuaid, S., Khawaja, H. A., Craig, S. G., James, J., Moore, W., McArt, D. G., Lawler, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12933 · Cited by 44
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations
Yao, Y.-M., Donoho, G. P., Iversen, P. W., Zhang, Y., Horn, R. D. V., Forest, A., Novosiadly, R. D., Webster, Y., Ebert, P. J., Bray, S. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3250 · Cited by 45
ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells.
Song, K., Yuan, Y., Lin, Y., Wang, Y., Zhou, J., Gai, Q., Zhang, L., Mao, M., Yao, X., Qin, Y., et al. (2018) · Europe PMC (PubMed Central) · Cited by 44
Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors
Wang, J., Pollard, K., Calizo, A., & Pratilas, C. A. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1992 · Cited by 44
MEK-Dependent Negative Feedback Underlies BCR–ABL-Mediated Oncogene Addiction
Asmussen, J. K., Lasater, E. A., Tajon, C. A., Osés-Prieto, J. A., Jun, Y., Taylor, B. S., Burlingame, A. L., Craik, C. S., & Shah, N. P. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0235 · Cited by 40
Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib
Doudican, N. A., & Orlow, S. J. (2016) · Oncogene · doi:10.1038/onc.2016.214 · Cited by 45
Liver protects metastatic prostate cancer from induced death by activating E‐cadherin signaling
Ma, B., Wheeler, S., Clark, A. M., Whaley, D., Yang, M. H., & Wells, A. H. (2016) · Hepatology · doi:10.1002/hep.28755 · Cited by 43
High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
Paulsson, J., Rydén, L., Strell, C., Frings, O., Tobin, N. P., Fornander, T., Bergh, J. C. S., Landberg, G., Stål, O., & Östman, A. (2016) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.56 · Cited by 43
TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells
Ungerleider, N., Han, C., Zhang, J., Yao, L., & Wu, T. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22592 · Cited by 45
Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells
Niepel, M., Hafner, M. A., Chung, M., & Sorger, P. K. (2017) · Current Protocols in Chemical Biology · doi:10.1002/cpch.21 · Cited by 42
Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform
Pant, S. M., Mukonoweshuro, A., Desai, B. K., Ramjee, M. K., Selway, C. N., Tarver, G. J., Wright, A. G., Birchall, K., Chapman, T. M., Tervonen, T. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01698 · Cited by 43
Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy
Dantonio, P. M., Klein, M., Freire, M. R. V. B., Araujo, C. D. N., Chiacetti, A. C., & Correa, R. G. (2018) · Bioscience Reports · doi:10.1042/bsr20180511 · Cited by 47
RTK Inhibitors in Melanoma: From Bench to Bedside
Sabbah, M., Najem, A., Krayem, M., Awada, A. H., Journé, F., & Ghanem, G. (2021) · Cancers · doi:10.3390/cancers13071685 · Cited by 46
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
Seip, K., Fleten, K. G., Barkovskaya, A., Nygaard, V., Haugen, M. H., Engesæter, B. Ø., Mælandsmo, G. M., & Prasmickaite, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7671 · Cited by 41
Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma
Connolly, K., Brungs, D., Szeto, E., & Epstein, R. J. (2013) · Current Oncology · doi:10.3747/co.21.1661 · Cited by 42
Cancer Secretomes and Their Place in Supplementing Other Hallmarks of Cancer
Patel, S. J., Wetie, A. G. N., Darie, C. C., & Clarkson, B. D. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-06068-2_20 · Cited by 42
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
Chen, F., Ishikawa, Y., Akashi, A., Naoe, T., & Kiyoi, H. (2016) · Oncotarget · doi:10.18632/oncotarget.10147 · Cited by 43
Ferroptosis: a new unexpected chance to treat metastatic melanoma?
Gagliardi, M., Saverio, V., Monzani, R., Ferrari, E., Piacentini, M., & Corazzari, M. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1806426 · Cited by 44
Mapping the Pathways of Resistance to Targeted Therapies
Wood, K. C. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1248 · Cited by 41
MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met
Xu, X., Jiang, W., Han, P., Zhang, J., Tong, L., & Sun, X. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s349369 · Cited by 41
Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells
He, C., Ali, D. J., Qi, Y., Li, Y., Sun, B., Liu, R., Sun, B., & Xiao, Z. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01902-6 · Cited by 40
Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
Corte, C. M. D., Fasano, M., Papaccio, F., Ciardiello, F., & Morgillo, F. (2014) · Biomedicines · doi:10.3390/biomedicines2040345 · Cited by 41
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway‐induced resistance to vascular endothelial growth factor receptor inhibitor
Nakagawa, T., Matsushima, T., Kawano, S., Nakazawa, Y., Kato, Y., Adachi, Y., Abe, T., Semba, T., Yokoi, A., Matsui, J., et al. (2014) · Cancer Science · doi:10.1111/cas.12409 · Cited by 41
MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure
Boccaccio, C., & Comoglio, P. M. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.09.008 · Cited by 42
Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML
Kampen, K. R., ter Elst, A., Mahmud, H., Scherpen, F. J. G., Diks, S. H., Peppelenbosch, M. P., de Haas, V., Guryev, V., & de Bont, E. S. J. M. (2013) · Leukemia · doi:10.1038/leu.2013.342 · Cited by 41
Analysis of growth factor signaling in genetically diverse breast cancer lines
Niepel, M., Hafner, M. A., Pace, E. A., Chung, M., Chai, D. H., Zhou, L., Muhlich, J. L., Schoeberl, B., & Sorger, P. K. (2014) · BMC Biology · doi:10.1186/1741-7007-12-20 · Cited by 41
Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy
Xie, Q. R., Su, Y., Dykema, K. J., Johnson, J. S., Koeman, J. M., Giorgi, V. D., Huang, A., Schlegel, R., Essenburg, C. J., Kang, L., et al. (2013) · Genes & Cancer · doi:10.1177/1947601913501075 · Cited by 41
Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation
Aldonza, M. B. D., Hong, J., Alinsug, M. V., Song, J., & Lee, S. K. (2016) · Oncotarget · doi:10.18632/oncotarget.9118 · Cited by 42
Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors
Peacock, J. D., Pridgeon, M. G., Tovar, E. A., Essenburg, C. J., Bowman, M. J., Madaj, Z., Koeman, J. M., Boguslawski, E. A., Grit, J. L., Dodd, R. D., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3167 · Cited by 41
Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC
Pham‐Danis, C., Gehrke, S. A., Danis, E. P., Rozhok, A. I., Daniels, M. W., Gao, D., Collins, C., Paola, J. T. D., D’Alessandro, A., & DeGregori, J. V. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1068 · Cited by 41
Heregulin induces resistance to lapatinib‐mediated growth inhibition of HER 2‐amplified cancer cells
Sato, Y., Yashiro, M., & Takakura, N. (2013) · Cancer Science · doi:10.1111/cas.12290 · Cited by 40
Microenvironment-mediated resistance to anticancer therapies
Olson, O. C., & Joyce, J. A. (2012) · Cell Research · doi:10.1038/cr.2012.123 · Cited by 39

Authors: Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., Ribas, A., Li, J., Moffat, J., Sutherlin, D. P., Koeppen, H., Merchant, M., Neve, R., & Settleman, J.
Affiliations: Genentech (US)
Vanderbilt University Medical Center (US)
University of California, Los Angeles (US)
Corresponding author: Settleman, Jeff
ORCID: Wilson, Timothy R.
Penuel, Elicia
Chan, Emily
Peng, Jing
Lin, Eva
Wang, Yulei
Ribas, Antoni
Koeppen, Hartmut
Merchant, Mark
Neve, Richard
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2012-07
Volume: 487
Issue: 7408
Pages: 505-509
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature11249
PMC: PMC3724525
OpenAlex: W1999025555
Cited by: 1,134
References: 29
Citations by year: 2026: 23 · 2025: 16 · 2024: 31 · 2023: 46 · 2022: 47 · 2021: 51 · 2020: 65 · 2019: 70 · 2018: 85 · 2017: 87 · 2016: 125 · 2015: 137 · 2014: 166 · 2013: 150 · 2012: 34
FWCI: 62.91
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: National Cancer Institute (K24CA097588)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: drug resistance, kinase inhibitors, receptor tyrosine kinase, growth factors, hepatocyte growth factor, BRAF inhibitors, vemurafenib, melanoma, tumor microenvironment, phosphatidylinositol 3-kinase, mitogen-activated protein kinase, combination therapy
MeSH terms: Lapatinib, Vemurafenib, Antineoplastic Agents, Breast Neoplasms, Cell Survival, Female, Humans, Indoles, Ligands, Melanoma, Quinazolines, Sulfonamides, Signal Transduction, Hepatocyte Growth Factor, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Receptor Protein-Tyrosine Kinases, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks